Video

Luspatercept in Lower-Risk MDS

Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.

Data from the following clinical trials are discussed:

  • 3098: Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study
  • 4408: Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study
  • 1774: Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial
  • 389: Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns
Related Videos
A panel of 5 experts on breast cancer
A panel of 5 experts on breast cancer
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
A panel of 5 experts on breast cancer
A panel of 5 experts on breast cancer
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma